Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial

lenvatinib, radioiodine-refractory differentiated cancer, thyroid

1. Pacini F., Ito Y., Luster M. et al. Radioactive iodine-refractory differentiated thyroid cancer: Unmet needs and future directions. Expert Rev Endocrinol Metab 2012;7:541–54.

2. Durante C., Haddy N., Baudin E. et al. Longterm outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892–9.

3. Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319–28.

4. Schlumberger M., Tahara M., Wirth L. J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372:621–30.

5. Okamoto K., Kodama K., Takase K. et al. Antitumor activities of the targeted multityrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013;340:97–103.

6. Yamamoto Y., Matsui J., Matsushima T. et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014;6:18.

7. Tohyama O., Matsui J., Kodama K. et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014;2014:638747.

8. Robbins R. J., Wan Q., Grewal R. K. et al. Realtime prognosis for metastatic thyroid carcinoma based on 2- [18F] fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498–505.

9. Xing M., Haugen B. R., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381:1058–69.

10. Eisenhauer E. A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.

11. National Cancer Institute: Protocol development: Cancer therapy evaluation program. Available at: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40

12. Eisai Inc: Lenvima (lenvatinib). [prescribing information].Woodcliff Lake, NJ, Eisai, 2015.

13. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Thyroid carcinoma. Version 1.2016. Fort Washington, PA, National Comprehensive Cancer Network, 2016.

14. Carhill A. A., Cabanillas M. E., Jimenez C. et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: Establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 2013;98:31–42.

15. Park H. S., Roman S. A., Sosa J. A. Treatment patterns of aging Americans with differentiated thyroid cancer. Cancer 2010;116:20–30.

16. Kornblith A. B., Kemeny M., Peterson B. L. et al. Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002;95:989–96.

17. Kemeny M. M., Peterson B. L., Kornblith A. B. et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003;21:2268–75.